The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
Open accessAbstract
Small molecule inhibitors that selectively target cancer cells and not normal cells would be valuable anti-cancer therapeutics. The mammalian target of rapamycin complex 2 (mTORC2) is emerging as a promising candidate target for such an inhibitor. Recent studies in cancer biology indicate that mTORC2 activity is essential for the transformation and vitality of a number of cancer cell types, but in many normal cells, mTORC2 activity is less essential. These studies are intensifying interest in developing inhibitors that specifically target mTORC2. However, there are many open questions regarding the function and regulation of mTORC2 and its function in both normal and cancer cells. Here, we summarize exciting new research into the biology of mTORC2 signaling and highlight the current state and future prospects for mTOR-targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Self-citationAKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Mechanism of activation of protein kinase B by insulin and IGF-1.
Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., & Hemmings, B. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01045.x · Cited by 3,004
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Self-citationThe Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773 · cited 1×
“In support, overexpressing or silencing Rheb has no effect on mTORC2 kinase activity (Yang et al., 2006b; Huang et al., 2008; Sancak et al., 2008).”
BackgroundTargeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Self-citationmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Laplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,114
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886
Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415
Self-citationJacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,410
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
The TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237 · cited 1×
“Interestingly, there is an emerging function for the TSC1–TSC2 complex in positively regulating mTORC2 (Huang et al., 2008, 2009).”
BackgroundPeterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202
The Double-Edged Sword of Autophagy Modulation in Cancer
White, E., & DiPaola, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5023 · Cited by 1,138
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
Kim, D.-H., Sarbassov, D. D., Ali, S. M., Latek, R. R., Guntur, K. V. P., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00114-x · Cited by 961
García-Martínez, J. M., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20081668 · Cited by 907
Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812
mSin1 Is Necessary for Akt/PKB Phosphorylation, and Its Isoforms Define Three Distinct mTORC2s
Frias, M. A., Thoreen, C. C., Jaffe, J. D., Schroder, W., Sculley, T., Carr, S. A., & Sabatini, D. M. (2006) · Current Biology · doi:10.1016/j.cub.2006.08.001 · Cited by 695
Nojima, H., Tokunaga, C., Eguchi, S., Oshiro, N., Hidayat, S., Yoshino, K.-I., Hara, K., Tanaka, N., Avruch, J., & Yonezawa, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200665200 · Cited by 682
Bentzinger, C. F., Romanino, K., Cloëtta, D., Lin, S., Mascarenhas, J. B., Oliveri, F., Xia, J., Casanova, E., Costa, C. F., Brink, M., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.10.002 · Cited by 640 · cited 2×
“Skeletal muscle is the first tissue in which mTORC2 activity has been conditionally ablated by Cre-mediated deletion of rictor ‘floxed’ alleles (Bentzinger et al., 2008; Kumar et al., 2008).”
BackgroundmTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes
Hresko, R. C., & Mueckler, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508361200 · Cited by 635
mTOR Is Essential for Growth and Proliferation in Early Mouse Embryos and Embryonic Stem Cells
Murakami, M., Ichisaka, T., Maeda, M., Oshiro, N., Hara, K., Edenhofer, F., Kiyama, H., Yonezawa, K., & Yamanaka, S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6710-6718.2004 · Cited by 624
An Emerging Role of mTOR in Lipid Biosynthesis
Laplante, M., & Sabatini, D. M. (2009) · Current Biology · doi:10.1016/j.cub.2009.09.058 · Cited by 620
Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling
Ikenoue, T., Inoki, K., Yang, Q., Zhou, X., & Guan, K. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.119 · Cited by 610
The Pharmacology of mTOR Inhibition
Guertin, D. A., & Sabatini, D. M. (2009) · Science Signaling · doi:10.1126/scisignal.267pe24 · Cited by 568
Self-citationAKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 524
TOS Motif-Mediated Raptor Binding Regulates 4E-BP1 Multisite Phosphorylation and Function
Schalm, S. S., Fingar, D. C., Sabatini, D. M., & Blenis, J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00329-4 · Cited by 520
Yang, Q., Inoki, K., Ikenoue, T., & Guan, K.-L. (2006) · Genes & Development · doi:10.1101/gad.1461206 · Cited by 517
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
Witzig, T. E., Geyer, S. M., Ghobrial, I., Inwards, D. J., Fonseca, R., Kurtin, P., Ansell, S. M., Luyun, R., Flynn, P. J., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.466 · Cited by 514
The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2
Huang, J., Dibble, C. C., Matsuzaki, M., & Manning, B. D. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00289-08 · Cited by 511
Facchinetti, V., Ouyang, W., Wei, H., Soto, N., Lazorchak, A., Gould, C., Lowry, C., Newton, A. C., Mao, Y., Miao, R. Q., et al. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.120 · Cited by 509
Crystal structure of an activated Akt/Protein Kinase B ternary complex with GSK3-peptide and AMP-PNP
Yang, J., Cron, P., Good, V. M., Thompson, V., Hemmings, B. A., & Barford, D. (2002) · Nature Structural Biology · doi:10.1038/nsb870 · Cited by 503
Gangloff, Y.-G., Mueller, M., Dann, S. G., Svoboda, P., Sticker, M., Spetz, J.-F., Um, S. H., Brown, E. J., Cereghini, S., Thomas, G., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9508-9516.2004 · Cited by 485 · cited 1×
“…developing mouse embryo, globally deleting mTOR or raptor results in early lethality, whereas deleting rictor or mSIN1 results in lethality around embryonic day 10.5 (Gangloff et al., 2004; Murakami et al., 2004; Guertin et al., 2006; Jacinto et al., 2006; Shiota et al., 2006; Yang et al., 2006a).”
BackgroundInfluentialIdentification of a Conserved Motif Required for mTOR Signaling
Schalm, S. S., & Blenis, J. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00762-5 · Cited by 482
Identification of Protor as a novel Rictor-binding component of mTOR complex-2
Pearce, L. R., Huang, X., Boudeau, J., Pawłowski, R., Wullschleger, S., Deak, M., Ibrahim, A. F. M., Gourlay, R., Magnuson, M. A., & Alessi, D. R. (2007) · Biochemical Journal · doi:10.1042/bj20070540 · Cited by 464
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
García-Martínez, J. M., Moran, J., Clarke, R. G., Gray, A., Cosulich, S. C., Chresta, C. M., & Alessi, D. R. (2009) · Biochemical Journal · doi:10.1042/bj20090489 · Cited by 455
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Phung, T. L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., Perruzzi, C., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 438
mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling
Julien, L.-A., Carriere, A., Moreau, J., & Roux, P. P. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00601-09 · Cited by 435
mTOR and cancer: many loops in one pathway
Efeyan, A., & Sabatini, D. M. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.10.007 · Cited by 430
Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1
Dibble, C. C., Asara, J. M., & Manning, B. D. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00735-09 · Cited by 423
Copp, J., Manning, G., & Hunter, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3014 · Cited by 422
Molecular Mechanism for the Regulation of Protein Kinase B/Akt by Hydrophobic Motif Phosphorylation
Yang, J., Cron, P., Thompson, V., Good, V. M., Hess, D., Hemmings, B. A., & Barford, D. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00550-6 · Cited by 418
Shiota, C., Woo, J.-T., Lindner, J., Shelton, K. D., & Magnuson, M. A. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.08.013 · Cited by 389
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR
Zhang, H., Bajraszewski, N., Wu, E., Wang, H., Moseman, A. P., Dabora, S. L., Griffin, J. D., & Kwiatkowski, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28984 · Cited by 381
Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans
Soukas, A. A., Kane, E. A., Carr, C. E., Melo, J. A., & Ruvkun, G. (2009) · Genes & Development · doi:10.1101/gad.1775409 · Cited by 380
mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
Guertin, D. A., Stevens, D. M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J.-H., Mullholland, D. J., Magnuson, M. A., Wu, H., & Sabatini, D. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.017 · Cited by 355
Self-citationRapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
Zeng, Z., Sarbassov, D. D., Samudio, I. J., Yee, K. W. L., Munsell, M. F., Ellen Jackson, C., Giles, F. J., Sabatini, D. M., Andreeff, M., & Konopleva, M. (2007) · Blood · doi:10.1182/blood-2006-06-030833 · Cited by 342
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Janes, M. R., Limon, J. J., So, L., Chen, J., Lim, R. J., Chavez, M. A., Vu, C., Lilly, M. B., Mallya, S., Ong, S. T., et al. (2010) · Nature Medicine · doi:10.1038/nm.2091 · Cited by 337
Yu, K., Toral-Barza, L., Shi, C., Zhang, W.-G., Lucas, J., Shor, B., Kim, J., Verheijen, J., Curran, K., Malwitz, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0299 · Cited by 330
PRAS40 and PRR5-Like Protein Are New mTOR Interactors that Regulate Apoptosis
Thedieck, K., Polak, P., Kim, M. L., Molle, K. D., Cohen, A., Jenö, P., Arrieumerlou, C., & Hall, M. N. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001217 · Cited by 296
Masri, J., Bernath, A., Martin, J., Jo, O. D., Vartanian, R., Funk, A., & Gera, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2223 · Cited by 253
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
Yuan, R., Kay, A., Berg, W. J., & Lebwohl, D. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-45 · Cited by 240
Molecular Organization of Target of Rapamycin Complex 2
Wullschleger, S., Loewith, R., Oppliger, W., & Hall, M. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505553200 · Cited by 234
Kumar, A., Harris, T. E., Keller, S. R., Choi, K. M., Magnuson, M. A., & Lawrence, J. C. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01405-07 · Cited by 216
Tor2 Directly Phosphorylates the AGC Kinase Ypk2 To Regulate Actin Polarization
Kamada, Y., Fujioka, Y., Suzuki, N. N., Inagaki, F., Wullschleger, S., Loewith, R., Hall, M. N., & Ohsumi, Y. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.16.7239-7248.2005 · Cited by 210
PIKKing on PKB: regulation of PKB activity by phosphorylation
Bozulic, L., & Hemmings, B. A. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.02.002 · Cited by 208
TOR regulation of AGC kinases in yeast and mammals
Jacinto, E., & Lorberg, A. (2008) · Biochemical Journal · doi:10.1042/bj20071518 · Cited by 205
Woo, S.-Y., Kim, D.-H., Jun, C.-B., Kim, Y.-M., Haar, E. V., Lee, S.-I., Hegg, J. W., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704343200 · Cited by 202
Nutrient control of TORC1, a cell-cycle regulator
Wang, X., & Proud, C. G. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2009.03.005 · Cited by 196
TOR Complex 2 Integrates Cell Movement during Chemotaxis and Signal Relay in Dictyostelium
Lee, S., Comer, F. I., Sasaki, A., McLeod, I. X., Duong, Y., Okumura, K., Yates, J. R., Parent, C. A., & Firtel, R. A. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-04-0342 · Cited by 196
Hayashi, T., Hatanaka, M., Nagao, K., Nakaseko, Y., Kanoh, J., Kokubu, A., Ebe, M., & Yanagida, M. (2007) · Genes to Cells · doi:10.1111/j.1365-2443.2007.01141.x · Cited by 191
Rictor/TORC2 Regulates Caenorhabditis elegans Fat Storage, Body Size, and Development through sgk-1
Jones, K. T., Greer, E. R., Pearce, D., & Ashrafi, K. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000060 · Cited by 191
Berchtold, D., & Walther, T. C. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-10-1001 · Cited by 189
TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity
Yang, Q., Inoki, K., Kim, E., & Guan, K.-L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602282103 · Cited by 184
Regulation of Ceramide Biosynthesis by TOR Complex 2
Aronova, S., Wedaman, K., Aronov, P. A., Fontes, K., Ramos, K., Hammock, B. D., & Powers, T. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.015 · Cited by 184
PIP3-Independent Activation of TorC2 and PKB at the Cell's Leading Edge Mediates Chemotaxis
Kamimura, Y., Xiong, Y., Iglesias, P. A., Hoeller, O., Bolourani, P., & Devreotes, P. N. (2008) · Current Biology · doi:10.1016/j.cub.2008.06.068 · Cited by 179
Serum and glucocorticoid‐regulated protein kinases: Variations on a theme
Tessier, M., & Woodgett, J. R. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20894 · Cited by 177
Gulhati, P., Cai, Q., Li, J., Liu, J., Rychahou, P. G., Qiu, S., Lee, E. Y., Silva, S. R., Bowen, K. A., Gao, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1249 · Cited by 177
Rictor is a novel target of p70 S6 kinase-1
Treins, C., Warne, P. H., Magnuson, M. A., Pende, M., & Downward, J. (2009) · Oncogene · doi:10.1038/onc.2009.401 · Cited by 175
mTOR complex 2 in adipose tissue negatively controls whole-body growth
Cybulski, N., Polak, P., Auwerx, J., Rüegg, M. A., & Hall, M. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811321106 · Cited by 174
Site-Specific mTOR Phosphorylation Promotes mTORC1-Mediated Signaling and Cell Growth
Acosta-Jaquez, H. A., Keller, J. A., Foster, K. G., Ekim, B., Soliman, G. A., Feener, E. P., Ballif, B. A., & Fingar, D. C. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01665-08 · Cited by 167
Targeting mTOR globally in cancer: Thinking beyond rapamycin
Shor, B., Gibbons, J. J., Abraham, R. T., & Yu, K. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10070 · Cited by 166
TOR1 and TOR2 Have Distinct Locations in Live Cells
Sturgill, T. W., Cohen, A., Diefenbacher, M., Trautwein, M., Martin, D. E., & Hall, M. N. (2008) · Eukaryotic Cell · doi:10.1128/ec.00088-08 · Cited by 159
Rapamycin inhibits trypanosome cell growth by preventing TOR complex 2 formation
Barquilla, A., Crespo, J. L., & Navarro, M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802668105 · Cited by 150
Fadri‐Moskwik, M., Daquinag, A. C., Wang, S., Xue, T., & Kunz, J. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0564 · Cited by 148
Re-evaluating AKT regulation: role of TOR complex 2 in tissue growth
Hietakangas, V., & Cohen, S. M. (2007) · Genes & Development · doi:10.1101/gad.416307 · Cited by 148
The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation
McManus, E. J., Collins, B., Ashby, P. R., Prescott, A. R., Murray-Tait, V., Armit, L. J., Arthur, J. S. C., & Alessi, D. R. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600218 · Cited by 146
Genome‐wide lethality screen identifies new PI4,5P2 effectors that regulate the actin cytoskeleton
Audhya, A., Loewith, R., Parsons, A. B., Gao, L., Tabuchi, M., Zhou, H., Boone, C. M., Hall, M. N., & Emr, S. D. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600384 · Cited by 140
Tabuchi, M., Audhya, A., Parsons, A. B., Boone, C. M., & Emr, S. D. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02403-05 · Cited by 139
Huang, J., Wu, S., Wu, C., & Manning, B. D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0975 · Cited by 138
Shor, B., Zhang, W., Toral‐Barza, L., Lucas, J., Abraham, R. T., Gibbons, J. J., & Yu, K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6487 · Cited by 131
Classical PKC isoforms in cancer
Martiny‐Baron, G., & Fabbro, D. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.04.001 · Cited by 129
Human Sin1 contains Ras-binding and pleckstrin homology domains and suppresses Ras signalling
Schroder, W. A., Buck, M., Cloonan, N., Hancock, J. F., Suhrbier, A., Sculley, T. B., & Bushell, G. R. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.01.013 · Cited by 125
Lee, S. D., Parent, C. A., Insall, R. H., & Firtel, R. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.9.2829 · Cited by 101
Drosophila Target of Rapamycin Kinase Functions as a Multimer
Zhang, Y., Billington, C. J., Pan, D., & Neufeld, T. P. (2005) · Genetics · doi:10.1534/genetics.105.051979 · Cited by 93
mTOR, A New Therapeutic Target in Acute Myeloid Leukemia
Récher, C., Santos, C. D., Demur, C., & Payrastre, B. (2005) · Cell Cycle · doi:10.4161/cc.4.11.2159 · Cited by 89
Koike-Kumagai, M., Yasunaga, K.-I., Morikawa, R., Kanamori, T., & Emoto, K. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.312 · Cited by 84
Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis
Nardella, C., Carracedo, A., Alimonti, A., Hobbs, R. M., Clohessy, J. G., Chen, Z., Egia, A., Fornari, A., Fiorentino, M., Loda, M. F., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000189 · Cited by 77
Witzig, T. E., & Kaufmann, S. H. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0038-1 · Cited by 74
Hietakangas, V., & Cohen, S. M. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-282 · Cited by 73
Desai, A. B., & Dogterom, M. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.01.003 · Cited by 71
Rapamycin regulates the phosphorylation of rictor
Akçakanat, A., Singh, G., Hung, M., & Meric‐Bernstam, F. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.07.151 · Cited by 63
RAG GTPases in nutrient-mediated TOR signaling pathway
Kim, E., & Guan, K. (2009) · Cell Cycle · doi:10.4161/cc.8.7.8124 · Cited by 36
The human stress-activated protein kinase-interacting 1 gene encodes JNK-binding proteins
Schroder, W. A., Bushell, G. R., & Sculley, T. B. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.10.015 · Cited by 34
Cited by
MTOR: a pharmacologic target for autophagy regulation
Kim, Y. C., & Guan, K.-L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73939 · Cited by 2,126
Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,241
Making new contacts: the mTOR network in metabolism and signalling crosstalk
Shimobayashi, M., & Hall, M. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3757 · Cited by 1,053
Activation of mTORC2 by Association with the Ribosome
Zinzalla, V., Stracka, D., Oppliger, W., & Hall, M. N. (2011) · Cell · doi:10.1016/j.cell.2011.02.014 · Cited by 654
mTOR complex 2 signaling and functions
Oh, W. J., & Jacinto, E. (2011) · Cell Cycle · doi:10.4161/cc.10.14.16586 · Cited by 562
Metadata
- Authors
- Sparks, C. A., & Guertin, D. A.
- Venue
- Oncogene
- Published
- 2010-04-26
- Volume
- 29
- Issue
- 26
- Pages
- 3733-3744
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1999211774
- Cited by
- 299
- References
- 104
- FWCI
- 13.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.